June 20th, 2024

Dr. Heather Brennan Joins inSoma Board of Directors

inSoma is pleased to announce the addition of Heather Brennan, Ph.D., to its Board of Directors. Dr. Brennan is passionate about women’s health and has 20 years of medical device and regenerative medicine experience. She currently serves as CEO of PracticeWise, a behavioral health company. Prior to PracticeWise, Dr. Brennan was General Manager, Global Markets at Establishment Labs where she managed a $165M global breast reconstruction and aesthetics business. She also previously served as Vice President and General Manager of MTF Biologics’ Plastic and Reconstructive Surgery Franchise, where she developed and led the strategic direction of the business, growing revenue by 500% and solidifying a leadership spot for the company in post-mastectomy breast reconstruction. Dr. Brennan received her Ph.D. in biomedical engineering from Rutgers University and her bachelor’s degree in mechanical engineering from Lehigh University.

February 28th, 2024

inSoma Appoints Head of Regulatory Affairs

inSoma is pleased to welcome Thalia Charles as its Head of Regulatory Affairs. In this role, Ms. Charles will support the advancement of inSoma’s regenerative reconstruction platform, Fractomer™, into clinical evaluation for its potential as a safe and natural option for patients opting for reconstruction. She brings 20 years’ experience steering medical devices through agency oversight to market, and deep expertise in the reconstruction and augmentation regulatory environment. Ms. Charles joins inSoma from Establishment Labs where she served as Senior Director of Global Regulatory Affairs. Prior to Establishment Labs, she served as Director of Regulatory Affairs for TransMedics, Inc. Across her career, she has successfully navigated the regulatory landscape for products including donor organ preservation systems, cancer screening products, and coagulopathy testing. She received her Master’s in developmental psychobiology from Indiana University–Bloomington and her B.S. in psychology from Brown University.

January 4th, 2024

Dr. Juliana Blum Joins inSoma Board of Directors

inSoma is pleased to announce the addition of Juliana Blum, Ph.D., to its Board of Directors. Dr. Blum is an expert in residence for NCBiotech and has spent over 20 years combining her scientific technical expertise with bioengineered regenerative tissue development. As a co-founder and former Executive Vice President of Corporate Development of Humacyte, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at a commercial scale, Dr. Blum brings deep expertise in building a novel biotechnology platform and advancing the company through late-stage clinical development. She received her doctorate in Molecular Biology from Loyola University Chicago with a focus in cardiovascular gene therapy and her bachelors’ degree at Carthage College in Wisconsin.